@article{4d471934d0134d81aa20699980734e46,
title = "The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer",
abstract = "Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.",
keywords = "ATX, HCC, LPA, LPAR1, NASH, chemoprevention, cirrhosis, fibrosis, hepatocellular carcinoma, non-alcoholic steatohepatitis",
author = "Erstad, {Derek J.} and Tager, {Andrew M.} and Yujin Hoshida and Fuchs, {Bryan C.}",
note = "Funding Information: DJE was supported by the National Cancer Institute under grant T32CA071345; AMT was supported by the National Heart, Lung, and Blood Institute under grant R01HL133153; YH was supported by the National Institute of Diabetes and Digestive and Kidney Diseases under grant R01DK099558, the European Union under grant ERC-2014-AdG-671231 HEPCIR, the Irma T. Hirschl Trust, and the US Department of Defense under grant number W81XWH-16–1–0363; BCF was supported by the National Cancer Institute under grant K01CA140861, and the National Institutes of Diabetes and Digestive and Kidney Diseases under grants R01DK104956 and U01DK104302. Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 The Author(s). Published with license by Taylor & Francis Group, LLC. {\textcopyright} 2017, {\textcopyright} Derek J. Erstad, Andrew M. Tager, Yujin Hoshida, and Bryan C. Fuchs.",
year = "2017",
month = may,
day = "4",
doi = "10.1080/23723556.2017.1311827",
language = "English (US)",
volume = "4",
journal = "Molecular and Cellular Oncology",
issn = "2372-3556",
publisher = "Taylor and Francis Ltd.",
number = "3",
}